Tokyo, June 27, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that the Ministry of Health and Social Development of the Russian Federation has approved the antiepileptic agent Zonegran(R) (zonisamide) as an adjunctive therapy in the treatment of adult epilepsy patients with partial seizures. Zonegran is the first product for which Eisai has received approval for in Russia.
The Russian pharmaceuticals market constitutes the 11th largest in the world and is expected to see high growth going forward). In light of this, Eisai established a representative office, overseen by its U.K. subsidiary Eisai Europe Limited, in Moscow in October 2007, and has since been working to complete product registration procedures. The company has already submitted marketing authorization applications for three more products－anticancer agent Halaven(R) (eribulin mesylate) and AMPA-type glutamate receptor antagonist FYCOMPA(R) (perampanel), both of which are global products, and antiepileptic agent Exalief(R) (brand name in the EU: Zebinix(R), under license from the originator BIAL-Portela & Ca S.A.).
Zonisamide is an antiepileptic drug (AED) originally created by Dainippon Pharmaceutical Co., Ltd. (currently Dainippon Sumitomo Pharma Co., Ltd.), for which Eisai holds development, manufacturing and marketing rights in Russia as well as in Europe, the United States and Asia.
Eisai has set the goals of entering the world's top 20 largest pharmaceuticals markets by fiscal 2015 and making contributions to more than 500 million patients as part of the company's great globalization era strategy outlined in its mid-term strategic plan "HAYABUSA." Eisai's enhancement of its product lineup and marketing framework in Russia underscores the company's commitment to increasing the benefits provided to patients and their families across the region.
About Eisai
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
June 27, 2012
Source: Eisai
Eisai (TSE: 4523) (U.S: ESALY)
From the Japan Corporate News Network
http://www.japancorp.net
Topic: Press release summary
View more news from these Sectors: Biotech, Drugs & OTC
|
